UPDATE: Aegis Capital Initiates Amarin Corporation with Buy, $25 PT; Risk-Mitigated Opportunity

Aegis Capital said on Monday that it initiated coverage on Amarin Corporation

with a Buy rating and a price target of $25. Aegis Capital said, "In our view, Amarin constitutes one of the most risk-mitigated opportunities in the biotechnology sector, as the firm's lead product candidate has already successfully demonstrated safety and efficacy in two randomized, placebo-controlled Phase 3 clinical trials. These studies were conducted under Special Protocol Assessments (SPAs) from the U.S. FDA." Amarin Corporation closed at $15.12 on Friday.